Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
View Patent ↗The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
1. A method of treating at least one disease state or condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis in a human patient in need, comprising orally administering to said patient an effective amount of an ileal brake hormone releasing composition in oral dosage form comprising at least one ileal brake hormone releasing compound and at least one HMG-Co-A reductase inhibitor wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is released in the ileum of the patient and wherein said HMG Co-A reductase inhibitor is formulated in said composition in immediate or controlled release form.
2. The method according to claim 1 wherein said disease state or condition is NASH.
3. The method according to claim 1 , wherein said patient is infected with hepatitis B or C and said at least one ileal brake hormone releasing composition and said HMG Co-A reductase inhibitor is coadministered with at least one antiviral agent.
4. The method according to claim 2 , wherein said patient is infected with hepatitis B or C and said at least one ileal brake hormone releasing composition and said HMG Co-A reductase inhibitor is coadministered with at least one antiviral agent.
5. The method according to claim 1 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
6. The method according to claim 2 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
7. The method according to claim 3 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
8. The method according to claim 4 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
9. The method according to claim 1 , wherein said HMG-CoA reductase inhibitor used in said ileal brake composition is given in a dosage of less than 30% of the dosage of said HMG-CoA reductase inhibitor when used alone.
10. The method according to claim 2 , wherein said HMG-CoA reductase inhibitor used in said ileal brake composition is given in a dosage of less than 30% of the dosage of said HMG-CoA reductase inhibitor when used alone.
11. The method according to claim 3 , wherein said HMG-CoA reductase inhibitor used in said ileal brake composition is given in a dosage of less than 30% of the dosage of said HMG-CoA reductase inhibitor when used alone.
12. The method according to claim 4 , wherein said HMG-CoA reductase inhibitor used in said ileal brake composition is given in a dosage of less than 30% of the dosage of said HMG-CoA reductase inhibitor when used alone.
13. The method according to claim 1 wherein said ileal brake hormone releasing composition comprises glucose or a combination of glucose and a lipid.
14. The method according to claim 2 wherein said ileal brake hormone releasing composition comprises glucose or a combination of glucose and a lipid.
15. The method according to claim 3 wherein said ileal brake hormone releasing composition comprises glucose or a combination of glucose and a lipid.
16. The method according to claim 4 wherein said ileal brake hormone releasing composition comprises glucose or a combination of glucose and a lipid.
17. A pharmaceutical composition in oral dosage form comprising an effective amount of an ileal brake hormone releasing composition comprising at least one ileal brake hormone releasing compound in combination with an effective amount of an antiviral agent wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is selectively released in the ileum of said patient and said antiviral agent is formulated in said composition in immediate or sustained release form.
18. The composition according to claim 17 wherein said antiviral agent is formulated in said composition in immediate release form.
19. A pharmaceutical composition in oral dosage form comprising an effective amount of an ileal brake hormone releasing composition comprising at least one ileal brake hormone releasing compound in combination with an effective amount of an additional bioactive agent wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is selectively released in the ileum of said patient and said additional bioactive agent is formulated in said composition in immediate or sustained release form.
20. The composition according to claim 19 wherein said additional bioactive agent is formulated in immediate release form.
21. The composition according to claim 19 wherein said additional bioactive agent is formulated in sustained release form.
22. The composition according to claim 19 wherein said additional bioactive agent is an anticancer agent effective for treating hepatocellular cancer.
23. The composition according to claim 22 wherein said anticancer agent is formulated in immediate release form.
24. The composition according to claim 22 wherein said anticancer agent is formulated in sustained release form.
25. The composition according to claim 19 wherein said bioactive agent is a biguanide antihyperglycemic agent, a DPP-IV inhibitor, a thiazolidinediones, a PPAR-sparing agent, an SGLT-2 inhibitor, an alpha glucosidase inhibitor, a glucokinase activator, a HMG-CoA reductase inhibitor, an angiotensin II inhibitor a phosphodiesterase type 5 inhibitor, an anti-obesity composition or mixtures thereof.
26. A method of treating non-alcoholic steatohepatitis (NASH) and/or liver fibrosis in a human patient in need, comprising orally administering to said patient an effective amount of an ileal brake hormone releasing composition in oral dosage form comprising at least one ileal brake hormone releasing compound and an HMG-Co-A reductase inhibitor wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is released in the ileum of the patient and wherein said HMG Co-A reductase inhibitor is formulated in said composition in immediate or controlled release form.
27. The method according to claim 26 wherein said disease state or condition is NASH and said HMG Co-A reductase inhibitor is formulated in said composition in immediate release form.
28. The method according to claim 26 wherein said disease state or condition is NASH and said HMG Co-A reductase inhibitor is formulated in said composition in sustained release form.
29. The method according to claim 26 , wherein said patient is infected with hepatitis B or C and said at least one ileal brake hormone releasing composition and said HMG Co-A reductase inhibitor is coadministered with at least one antiviral agent.
30. The method according to claim 27 , wherein said patient is infected with hepatitis B or C and said at least one ileal brake hormone releasing composition and said HMG Co-A reductase inhibitor is coadministered with at least one antiviral agent.
31. The method according to claim 26 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
32. The method according to claim 27 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
33. The method according to claim 28 , wherein said HMG-CoA reductase inhibitor is at least one agent selected from the group consisting of atorvastatin, simvastatin, lovastatin, ceruvastatin, pravastatin and pitavastatin.
34. A method of treating a disease state or condition selected from the group consisting of non-alcoholic steatohepatitis (NASH), liver fibrosis or a combination thereof in a human patient in need, comprising orally administering to said patient an effective amount of an ileal brake hormone releasing composition in oral dosage form comprising at least one ileal brake hormone releasing compound wherein at least 50% by weight of the ileal brake hormone releasing compound administered to said patient is released in the ileum of the patient in an amount effective to upregulate ileal brake hormones in said patient and treat said disease state or condition.
35. The method according to claim 34 wherein said ileal brake hormone releasing composition comprises glucose or a combination of glucose and a lipid.
36. The method according to claim 35 wherein said lipid is cottonseed oil, a nut oil, coconut oil, palm oil, corn oil, germ oil, olive oil, castor oil, sesame oil, fish oil, oleic acid or a liver derived oil.
37. The method according to claim 35 wherein said ileal brake hormone releasing compound is about 7.5 grams to about 12.5 grams per dose.
38. The method according to claim 37 wherein said oral dosage form is co-administered with a HMG-CoA reductase inhibitor and/or an antiviral agent.
39. The method according to claim 37 wherein said oral dosage form includes a HMG-CoA reductase inhibitor, an anti-viral agent or mixtures thereof in immediate, sustained and/or controlled release form.